Kobayashi Kyoko, Nakagami-Yamaguchi Etsuko, Hayakawa Akira, Adachi Souichi, Hara Junichi, Tokimasa Sadao, Ohta Hideaki, Hashii Yoshiko, Rikiishi Takeshi, Sawada Machiko, Kuriyama Kikuko, Kohdera Urara, Kamibeppu Kiyoko, Kawasaki Hirohide, Oda Megumi, Hori Hiroki
Department of Child Health Nursing, St Luke's International University Graduate School of Nursing Science, Chuo, Japan.
Department of Medical Quality and Safety Science, Osaka City University Graduate School of Medicine, Abeno, Japan.
Pediatr Int. 2017 Feb;59(2):145-153. doi: 10.1111/ped.13092. Epub 2016 Oct 20.
Quality of life (QOL) as a treatment outcome has not yet been evaluated among patients receiving a specific treatment regimen by treatment phase in a consistent manner. This exploratory cross-sectional study evaluated the QOL of children with acute lymphoblastic leukemia (ALL) receiving one of the most popular treatment regimens in Japan (Japan Association of Childhood Leukemia Study ALL-02 revised protocol).
Children aged 5-18 years with newly diagnosed B-cell precursor ALL were included. The Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL-J) were completed by children with ALL and their siblings, as well as by age- and sex-matched healthy controls. PedsQL Cancer Module (PedsQL-C) scores were also collected from children with ALL.
QOL in children with ALL of the consolidation phase group was significantly decreased compared with that of healthy controls, except in the area of emotional functioning. Regarding the maintenance phase group, QOL impairment was noted in the physical and school functioning, but no differences were noted in social functioning. The off-treatment group had a large effect size only for physical functioning, and the social functioning score was even better in children with ALL than in matched controls. QOL of children with ALL differed with treatment phase. Effect size varied with function and treatment phase.
QOL may change with the progression of treatment, and the timing of these changes varied according to function and problem.
作为治疗结果的生活质量（QOL）尚未在接受特定治疗方案的患者中按治疗阶段进行一致评估。这项探索性横断面研究评估了接受日本最常用治疗方案之一（日本儿童白血病研究协会ALL - 02修订方案）的急性淋巴细胞白血病（ALL）儿童的生活质量。
纳入5 - 18岁新诊断为B细胞前体ALL的儿童。ALL儿童及其兄弟姐妹以及年龄和性别匹配的健康对照完成了儿童生活质量量表4.0通用核心量表（PedsQL - J）。还收集了ALL儿童的儿童生活质量量表癌症模块（PedsQL - C）得分。
巩固期组ALL儿童的生活质量与健康对照相比显著下降，但在情感功能领域除外。关于维持期组，在身体和学校功能方面发现生活质量受损，但在社会功能方面未发现差异。停止治疗组仅在身体功能方面有较大效应量，且ALL儿童的社会功能得分甚至优于匹配对照。ALL儿童的生活质量因治疗阶段而异。效应量随功能和治疗阶段而变化。
生活质量可能随治疗进展而变化，且这些变化的时间根据功能和问题而有所不同。
